Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective is to demonstrate that LY2605541 is noninferior to insulin glargine for the change in HbA1c from baseline to 26 weeks of treatment in patients with T2DM treated with basal insulin alone or in combination with oral antihyperglycemic medication(s) (OAMs)
Critère d'inclusion
- Type 2 diabetes mellitus